How to Suppress Appetite: UK Guide

How to suppress appetite is a question rooted in biology as much as behaviour. Hunger is governed by a complex network of hormones, including ghrelin, leptin and GLP-1, which means that willpower alone is rarely sufficient for long-term appetite control. This article explains what drives hunger, outlines evidence-based lifestyle strategies, reviews prescription options available in the UK such as semaglutide (Wegovy) and tirzepatide (Mounjaro), covers their safety profiles and side effects, and advises when to speak to a GP or pharmacist about appetite management.

Why do we feel hungry, and what drives appetite?

Hunger is driven by hormones including ghrelin, leptin, GLP-1 and peptide YY, coordinated between the gut, fat tissue and hypothalamus. Poor sleep, stress and low-protein meals can disrupt these signals, making appetite hard to control through willpower alone.

Hunger is regulated primarily by a network of hormones and brain signals that communicate energy needs between the gut, fat tissue and the hypothalamus. The two most studied hormones are ghrelin, which rises before meals and stimulates hunger, and leptin, which is released by fat cells and signals fullness.^[1][2] Other satiety signals include peptide YY (PYY), cholecystokinin (CCK), insulin and GLP-1, all of which contribute to the feeling of fullness after eating. When these signals fall out of balance, for example after significant weight loss or poor sleep, appetite can become difficult to manage through willpower alone.

Several factors influence how hungry a person feels on any given day:

• Sleep quality: Even one night of poor sleep can raise ghrelin and lower leptin, increasing appetite the following day.^[3][4]

• Stress: Elevated cortisol promotes cravings for calorie-dense foods.

• Meal composition: Foods low in protein and fibre are digested quickly, causing blood glucose to rise and fall sharply, which triggers renewed hunger sooner.

• Gut microbiome: Emerging research suggests that the balance of bacteria in the gut may influence appetite-regulating hormones, though this field is still developing.

Understanding these mechanisms is important because it explains why appetite suppression is rarely as simple as eating less. Biological drives can override conscious decisions, and for some people the hormonal environment makes sustained calorie reduction genuinely difficult. Recognising this removes the stigma around seeking support and helps frame appetite management as a medical question rather than a matter of self-discipline.

How can you suppress appetite safely without medication?

High-protein meals, soluble fibre, adequate hydration, slow eating, seven to nine hours of sleep and stress management are the most evidence-supported non-medication strategies for reducing appetite.

Several evidence-informed lifestyle strategies can meaningfully reduce appetite without the need for medication. Prioritising protein at each meal is one of the most effective approaches: protein stimulates the release of satiety hormones such as peptide YY and GLP-1, and reduces ghrelin more than carbohydrate or fat does.^[5] Aiming for a source of protein at breakfast, such as eggs, Greek yoghurt or legumes, can reduce overall calorie intake across the day.

Fibre-rich foods, particularly soluble fibre found in oats, lentils, apples and flaxseed, slow gastric emptying and prolong the feeling of fullness. If you are increasing your fibre intake, do so gradually and drink plenty of fluids alongside, as a sudden large increase can cause bloating or digestive discomfort. Drinking water before and during meals also contributes to satiety, and research suggests that people sometimes interpret thirst as hunger. Eating slowly and without distraction allows the gut-brain satiety signals, which take roughly 15 to 20 minutes to register, to catch up with food intake.

Sleep and stress management are often overlooked but are clinically relevant. Consistently sleeping seven to nine hours per night helps maintain a healthier hormonal balance, while techniques such as mindfulness, structured breathing or cognitive behavioural approaches can reduce stress-driven eating. Regular physical activity, particularly resistance training, has also been shown to improve appetite regulation over time, even though it may temporarily increase hunger in the short term.

These strategies are most effective when combined rather than used in isolation. For people with obesity or significant metabolic risk, lifestyle measures alone may be insufficient, and a conversation with a GP or registered dietitian is appropriate.

Which prescription appetite suppressants are available in the UK?

MHRA-authorised options include semaglutide (Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), orforglipron (Foundayo) and orlistat; eligibility depends on BMI, comorbidities and individual clinical assessment.

Several prescription medicines are available in the UK that reduce appetite as part of a broader approach to weight management, and the most clinically established belong to the GLP-1 receptor agonist class. Semaglutide (Wegovy) is authorised by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.^[6] The injectable form is administered as a weekly subcutaneous injection and works by mimicking the GLP-1 hormone, slowing gastric emptying and reducing appetite signals in the brain. Wegovy injection is available in doses up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA. An oral form, Wegovy 25 mg tablets, received MHRA approval in June 2026 for weight management and has a distinct dosing schedule from the injection; patients should follow the prescribing information specific to the tablet formulation.^[9] Liraglutide (Saxenda) is an earlier GLP-1 receptor agonist given as a daily injection and is also MHRA-authorised for weight management.

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist authorised by the MHRA for both type 2 diabetes and chronic weight management. It is delivered via a multiple-dose KwikPen, with one pen containing four weekly doses. Orforglipron (Foundayo) is an oral GLP-1 receptor agonist that has also received UK authorisation for weight management; patients should refer to its prescribing information for dosing details.^[12][13]

NICE has issued guidance on both semaglutide and tirzepatide for weight management, and local Integrated Care Boards (ICBs) make commissioning decisions about NHS availability in their area.

Orlistat is an older option that works differently, blocking fat absorption in the gut rather than acting on appetite directly. The 120 mg strength is available on prescription, while the 60 mg strength is a licensed Pharmacy (P) medicine supplied under pharmacist supervision at a pharmacy counter; it is not available from general retail shelves.^[14][15] Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro or other options may be considered if clinically appropriate.

No prescription appetite suppressant should be used without medical supervision, and eligibility depends on individual clinical assessment.

Are appetite suppressant pills safe, and what are the side effects?

GLP-1 medicines most commonly cause nausea and gastrointestinal upset; serious risks include acute pancreatitis and gallbladder disease, and they are contraindicated in pregnancy and breastfeeding.

The safety profile of appetite suppressants varies considerably depending on the medicine, and no treatment is without risk. GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda) most commonly cause gastrointestinal side effects, including nausea, vomiting, diarrhoea and constipation. These effects are usually most pronounced during dose escalation and tend to improve over time. Starting at a low dose and increasing gradually, as specified in the prescribing schedule, helps to minimise them.

Acute pancreatitis has been reported with GLP-1 receptor agonists, including post-marketing reports of necrotising pancreatitis and cases with a fatal outcome.^[16] Patients should be aware of the symptoms of pancreatitis, which include persistent and severe abdominal pain that may radiate to the back, and should seek prompt medical attention if these occur. GLP-1 receptor agonists have also been associated with gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis); if you develop upper abdominal pain, particularly after eating, tell your prescriber.^[16] The UK SmPCs for these medicines also note that cases of diabetic retinopathy worsening have been observed in people with pre-existing diabetic eye disease, particularly pre-proliferative or proliferative retinopathy, in the context of rapid glycaemic improvement.^[19][20]

For people who are pregnant or could become pregnant, GLP-1 and dual GIP/GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding. The Mounjaro SmPC advises using an additional non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, as the medicine may reduce the absorption of oral contraceptives.^[17]

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Some products marketed as appetite suppressants are unlicensed food supplements rather than licensed medicines; these are not subject to the same regulatory scrutiny as MHRA-authorised medicines, and their safety and efficacy are often poorly evidenced. By contrast, orlistat 60 mg is a licensed Pharmacy medicine with MHRA oversight, supplied under pharmacist supervision. If you are considering any over-the-counter product for appetite or weight management, speak to a pharmacist or GP before use.

When should you talk to your GP about appetite control?

See a GP if appetite remains unmanageable despite lifestyle changes, if unexplained rapid weight gain occurs, or if symptoms such as excessive thirst or frequent urination suggest an underlying condition such as diabetes.

A conversation with a GP is appropriate when appetite feels consistently difficult to manage despite reasonable lifestyle changes, or when uncontrolled hunger is contributing to significant weight gain or affecting quality of life. GPs can assess whether an underlying condition, such as hypothyroidism, polycystic ovary syndrome or insulin resistance, may be driving increased appetite, and can arrange relevant investigations in line with NICE guidance.

You should contact your GP if you notice:

• Unexplained or rapid weight gain that does not correspond to changes in diet or activity.

• Persistent hunger even after eating adequate portions, which may suggest a hormonal or metabolic issue.

• Binge eating or loss of control around food, which may benefit from psychological support or referral to a specialist eating disorders service.

• Symptoms suggesting a serious cause, such as excessive thirst, frequent urination or fatigue, which could indicate undiagnosed diabetes.

If you experience symptoms such as excessive thirst, frequent urination and unexplained weight loss alongside acute illness, seek same-day medical assessment rather than waiting for a routine appointment.

For people with a BMI that meets the threshold for prescription weight-management treatment, a GP can discuss referral to a specialist weight management service or initiate treatment directly, depending on local ICB commissioning arrangements. NICE technology appraisals provide guidance on which medicines may be recommended, but NHS availability is determined locally.

If you experience sudden severe abdominal pain, persistent vomiting or signs of an allergic reaction while taking any appetite suppressant, contact NHS 111 for urgent advice or attend A&E if symptoms are life-threatening. For routine concerns about appetite, weight or medication side effects, your GP is the right first point of contact.

Scientific References

1. Neuroendocrine regulation of appetite and energy balance in metabolic disorders.
2. Peptide Hormones in Appetite Regulation: A Complex Network.
3. Effects of acute sleep loss on leptin, ghrelin, and adiponectin.
4. Late, but Not Early, Night Sleep Loss Compromises Neuroendocrine Appetite Regulation and the Desire for Food.
5. Effect of short- and long-term protein consumption on appetite and appetite-regulating hormones.
6. Semaglutide for managing overweight and obesity (TA875).
7. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
8. Medicines regulator approves up to 7.2 mg dose of semaglutide/Wegovy for patients with obesity only.
9. First GLP-1 tablet for weight loss approved in the UK.
10. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
11. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
12. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
13. New oral GLP-1 medicine for weight management and type 2 diabetes (Foundayo/orforglipron).
14. Orlistat: a medicine to treat obesity.
15. Orlistat – BNF drug monograph.
16. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
17. Women on 'skinny jabs' must use effective contraception – MHRA urges in latest guidance.
18. Tirzepatide for managing overweight and obesity (TA1026).
19. NG242 Diabetic retinopathy: management and monitoring – evidence on intensive glucose-lowering and early worsening.
20. Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: a post-hoc analysis from a randomised trial.

Frequently Asked Questions